Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 7 7 7 versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 7 7 7 versus TRI SPRINTEC.
CYCLAFEM 7/7/7 vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Ethinyl estradiol suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis; norethindrone induces endometrial changes that inhibit implantation and thickens cervical mucus.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 0.75 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days. Dispensed in a 21-tablet pack with 7 placebo tablets. For contraception, take one tablet daily at same time each day for 28 days; begin next pack after 28-day cycle.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
Terminal half-life: 5-13 hours (mean 8 hrs); clinical context: supports every-28-day dosing interval for intramuscular depot.
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal: ~50-60% as conjugated metabolites; Fecal: ~30-40% via bile; <1% unchanged.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive